The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the representatives of the several underwriters in connection with a public offering by Ionis Pharmaceuticals, Inc. of 11,500,000 shares of common stock for total gross proceeds of approximately $500.3 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “IONS.”

For three decades as a pioneer in RNA-targeted medicines, Ionis Pharmaceuticals has focused on bringing better futures to people with serious diseases. Ionis Pharmaceuticals is headquartered in Carlsbad, California.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Dana Lueck-Mammen, Dove Barbanel and Savannah J. Dowling. Partner David R. Bauer and associates Jordan Khorshad and Jay Krishnan provided intellectual property advice. Partner Mario J. Verdolini and associates Albert Park and Isaiah B. Kramer provided tax advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post